Cargando…

Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39

The human bitter taste receptor hTAS2R39 can be activated by many dietary (iso)flavonoids. Furthermore, hTAS2R39 activity can be blocked by 6-methoxyflavanones, 4’-fluoro-6-methoxyflavanone in particular. A structure-based pharmacophore model of the hTAS2R39 binding pocket was built using Snooker so...

Descripción completa

Detalles Bibliográficos
Autores principales: Roland, Wibke S. U., Sanders, Marijn P. A., van Buren, Leo, Gouka, Robin J., Gruppen, Harry, Vincken, Jean-Paul, Ritschel, Tina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346584/
https://www.ncbi.nlm.nih.gov/pubmed/25729848
http://dx.doi.org/10.1371/journal.pone.0118200
_version_ 1782359713484111872
author Roland, Wibke S. U.
Sanders, Marijn P. A.
van Buren, Leo
Gouka, Robin J.
Gruppen, Harry
Vincken, Jean-Paul
Ritschel, Tina
author_facet Roland, Wibke S. U.
Sanders, Marijn P. A.
van Buren, Leo
Gouka, Robin J.
Gruppen, Harry
Vincken, Jean-Paul
Ritschel, Tina
author_sort Roland, Wibke S. U.
collection PubMed
description The human bitter taste receptor hTAS2R39 can be activated by many dietary (iso)flavonoids. Furthermore, hTAS2R39 activity can be blocked by 6-methoxyflavanones, 4’-fluoro-6-methoxyflavanone in particular. A structure-based pharmacophore model of the hTAS2R39 binding pocket was built using Snooker software, which has been used successfully before for drug design of GPCRs of the rhodopsin subfamily. For the validation of the model, two sets of compounds, both of which contained actives and inactives, were used: (i) an (iso)flavonoid-dedicated set, and (ii) a more generic, structurally diverse set. Agonists were characterized by their linear binding geometry and the fact that they bound deeply in the hTAS2R39 pocket, mapping the hydrogen donor feature based on T5.45 and N3.36, analogues of which have been proposed to play a key role in activation of GPCRs. Blockers lack hydrogen-bond donors enabling contact to the receptor. Furthermore, they had a crooked geometry, which could sterically hinder movement of the TM domains upon receptor activation. Our results reveal characteristics of hTAS2R39 agonist and bitter blocker binding, which might facilitate the development of blockers suitable to counter the bitterness of dietary hTAS2R39 agonists in food applications.
format Online
Article
Text
id pubmed-4346584
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43465842015-03-17 Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39 Roland, Wibke S. U. Sanders, Marijn P. A. van Buren, Leo Gouka, Robin J. Gruppen, Harry Vincken, Jean-Paul Ritschel, Tina PLoS One Research Article The human bitter taste receptor hTAS2R39 can be activated by many dietary (iso)flavonoids. Furthermore, hTAS2R39 activity can be blocked by 6-methoxyflavanones, 4’-fluoro-6-methoxyflavanone in particular. A structure-based pharmacophore model of the hTAS2R39 binding pocket was built using Snooker software, which has been used successfully before for drug design of GPCRs of the rhodopsin subfamily. For the validation of the model, two sets of compounds, both of which contained actives and inactives, were used: (i) an (iso)flavonoid-dedicated set, and (ii) a more generic, structurally diverse set. Agonists were characterized by their linear binding geometry and the fact that they bound deeply in the hTAS2R39 pocket, mapping the hydrogen donor feature based on T5.45 and N3.36, analogues of which have been proposed to play a key role in activation of GPCRs. Blockers lack hydrogen-bond donors enabling contact to the receptor. Furthermore, they had a crooked geometry, which could sterically hinder movement of the TM domains upon receptor activation. Our results reveal characteristics of hTAS2R39 agonist and bitter blocker binding, which might facilitate the development of blockers suitable to counter the bitterness of dietary hTAS2R39 agonists in food applications. Public Library of Science 2015-03-02 /pmc/articles/PMC4346584/ /pubmed/25729848 http://dx.doi.org/10.1371/journal.pone.0118200 Text en © 2015 Roland et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Roland, Wibke S. U.
Sanders, Marijn P. A.
van Buren, Leo
Gouka, Robin J.
Gruppen, Harry
Vincken, Jean-Paul
Ritschel, Tina
Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39
title Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39
title_full Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39
title_fullStr Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39
title_full_unstemmed Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39
title_short Snooker Structure-Based Pharmacophore Model Explains Differences in Agonist and Blocker Binding to Bitter Receptor hTAS2R39
title_sort snooker structure-based pharmacophore model explains differences in agonist and blocker binding to bitter receptor htas2r39
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346584/
https://www.ncbi.nlm.nih.gov/pubmed/25729848
http://dx.doi.org/10.1371/journal.pone.0118200
work_keys_str_mv AT rolandwibkesu snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39
AT sandersmarijnpa snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39
AT vanburenleo snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39
AT goukarobinj snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39
AT gruppenharry snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39
AT vinckenjeanpaul snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39
AT ritscheltina snookerstructurebasedpharmacophoremodelexplainsdifferencesinagonistandblockerbindingtobitterreceptorhtas2r39